Vanguard Investments Australia
CGON icon

Vanguard Investments Australia’s CG Oncology CGON Stock Holding History

Vanguard Investments Australia’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$940K Buy
13,229
+2,234
+20% +$146K ﹤0.01% 1315
2026
Q1 		$744K Buy
+10,995
New +$623K ﹤0.01% 1368

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Investments Australia's CGON Position: Q2 2026 in Review

Vanguard Investments Australia increased its CG Oncology (CGON) stake by 20% in Q2 2026, buying an estimated $146K and bringing the position to 13,229 shares worth $940K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Vanguard Investments Australia first reported a position in CGON in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Vanguard Investments Australia held 13,229 shares of CG Oncology worth $940K as of Q2 2026.
  • Vanguard Investments Australia bought 2,234 CG Oncology shares in Q2 2026, an estimated $146K.
  • CG Oncology made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1315 holding.
  • Vanguard Investments Australia first reported a position in CG Oncology in Q1 2026 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.